Etanercept-induced erythema nodosum in a patient with rheumatoid arthritis: Case report and literature review
Etanercept-induced erythema nodosum in a patient with rheumatoid arthritis: Case report and literature review
复制标题
类风湿性关节炎患者依那西普诱发结节性红斑:病例报告及文献复习
DOI:
10.1111/1346-8138.16636
复制
发表时间:
2023
期刊:
影响因子:
--
通讯作者:
Fujimoto M.
中科院分区:
文献类型:
--
作者:
Kurokami Y;Ueda-Hayakawa I;Fujimoto M.
Etanercept is a recombinant soluble tumor necrosis factor α (TNF-α) receptor used to treat inflammatory disorders. Here, we report a case of a patients with rheumatoid arthritis (RA) who developed erythema nodosum (EN) caused by etanercept infusion for RA management.A 76-year-old woman complained of fever over 38 C and skin lesions from the day before presentation. She had a history of RA and started therapy with etanercept infusion 20 days before presentation, and her most recent infusion was 4 days before her presentation. Her joint pain improved with etanercept. Physical examination revealed palpable painful erythema on her extremities and trunk (Figure 1a). Blood tests showed normal white blood cell count, elevated C-reactive protein (13.91 mg/dL), and decreased platelets (83 000 per μL). Additional laboratory tests, including antinuclear antibody and antineutrophil cytoplasmic antibody, were normal. A skin biopsy was performed for her right lower leg lesion. Histopathology demonstrated septal panniculitis with infiltration of neutrophils, lymphocytes, and nuclear dust, while Miescher's radial granuloma was absent (Figure 1b, c). Because the pathology did not show lobular panniculitis or lipoatrophy or lipophagia, Weber-Christian disease was excluded. Tissue culture was performed and the results were negative. These findings were consistent with EN.